GLP-1 Pill Rybelsus approved for Type 2 

The first GLP-1 agonist pill for Type 2 diabetes has been approved by the European Medicines Agency (EMA). Rybelsus (known as oral semaglutide in clinical trials) is a once-daily tablet version of Ozempic, a GLP-1 agonist injection, to be taken alone or in combination with other treatments for Type 2 diabetes.   

Rybelsus, manufactured by Novo Nordisk, was approved in the US in September 2019. This approval provides more options for people with Type 2 diabetes – data shows that Rybelsus lowers blood glucose and improves heart health, reducing the risk of heart attack, stroke, and heart-related death. 

Talk with your diabetes team for more information. 

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags